Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Avricore Health Inc V.AVCR

Alternate Symbol(s):  AVCRF

Avricore Health Inc. is a pharmacy service innovator focused on acquiring and developing early-stage technologies aimed at advancing pharmacy practice and patient care. The Company is involved in the business of health data and point-of-care technologies (POCT). HealthTab, its flagship offering, is a turnkey point-of-care testing solution that combines point-of-care technologies with a secure, cloud-based platform for tackling pressing global health issues. With just a few drops of blood from a finger prick, the system generates lab-accurate results on the spot and data is reported in real time. The test menu includes up to 23 key biomarkers for screening and managing chronic diseases, such as diabetes and heart disease (e.g., HbA1c, Lipid Profile, eGFR). The HealthTab also has capabilities for bacterial and viral tests, such as strep and COVID-19. The HealthTab platform transforms pharmacies into community point-of-care diagnostic centers.


TSXV:AVCR - Post by User

Bullboard Posts
Comment by hydrabioon May 10, 2017 10:20am
94 Views
Post# 26225376

RE:RE:RE:RE:RE:Q1 Out

RE:RE:RE:RE:RE:Q1 Out
You think Mint, Natco and Glenmark in Canada are "large"? No they are not and they received listings that are in the range of $3M-$10M each with new product listings with banners and accounts. If you had access to competitive IMS data you would see market growth and all generic growth and then Vanc which is way below industry. Again im talking generic companies in Canada, not brand companies. The concern I see is that they ship product, ex-factory, into wholesalers (ie McKesson or K&F) but have trouble moving ALL that product out to pharmacy. It ages and comes back as short dated. Also you will continue to see write downs on stock due to aging inventory when you see when they brought in product and how long its been in Canada. Their average stability 2 years with some possibilities of 3 years. The industry wants product with 1 year dating, CAPDM papers recommend 9 months dating and manufactures do a full stock on product that has 6 months dateing left. This is a concern with the aging product they have and that is in the Canadian supply chain.
Bullboard Posts